Palovarotene Patent Expiration
Palovarotene is Used for reducing heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva. It was first introduced by Ipsen Biopharmaceuticals Inc
Palovarotene Patents
Given below is the list of patents protecting Palovarotene, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Sohonos | US10864194 | Methods for treating heterotopic ossification | Jun 08, 2037 | Ipsen |
| Sohonos | US11622959 | Methods for treating heterotopic ossification | Jun 08, 2037 | Ipsen |
| Sohonos | US10292954 | Composition and method for muscle repair and regeneration | Aug 31, 2031 | Ipsen |
| Sohonos | US12023312 | Composition and method for muscle repair and regeneration | Aug 31, 2031 | Ipsen |
| Sohonos | US9314439 | Composition and method for muscle repair and regeneration | Aug 31, 2031 | Ipsen |
| Sohonos | US9789074 | Composition and method for muscle repair and regeneration | Aug 31, 2031 | Ipsen |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Palovarotene's patents.
Latest Legal Activities on Palovarotene's Patents
Given below is the list recent legal activities going on the following patents of Palovarotene.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 May, 2024 | US10864194 |
| Second letter to regulating agency to determine regulatory review period | 14 Mar, 2024 | US9314439 |
| Second letter to regulating agency to determine regulatory review period | 14 Mar, 2024 | US10292954 |
| Second letter to regulating agency to determine regulatory review period | 14 Mar, 2024 | US11622959 |
| Second letter to regulating agency to determine regulatory review period | 14 Mar, 2024 | US10864194 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US11622959 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US10864194 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US10292954 |
| Letter from FDA or Dept of Agriculture re PTE application | 06 Feb, 2024 | US9314439 |
| Initial letter Re: PTE Application to regulating agency | 22 Nov, 2023 | US10292954 |
Palovarotene's Family Patents
